8438 Journal of Medicinal Chemistry, 2010, Vol. 53, No. 23
Kmentova et al.
Supporting Information Available: Additional experimental
procedures and characterizations for compounds in Tables 1-3;
combustion analytical data. This material is available free of
bicyclic compounds as modulators of PPAR, and their prepara-
tion, pharmaceutical compositions and use for treatment of various
diseases. Patent WO 2006055187 A1, 2006.
(19) van Poucke, R.; Pollet, R.; de Cat, A. Preparation of aryl difluor-
omethyl ether, thioether and sulphone derivatives. Electronic
properties of the difluoromethoxy, -methylthio, and -methylsul-
phonyl substituents. Tetrahedron Lett. 1965, 6, 403–406.
(20) Biagetti, M.; Contini, S. A.; Genski, T.; Guery, S.; Leslie, C. P.;
Mazzali, A.; Pizzi, D. A.; Sabbatini, F. M.; Seri, C. Spiro com-
pounds as NPYY5 receptor antagonists and their preparation,
pharmaceutical compositions and use in the treatment of eating
disorders. Patent WO 2009095377 A1, 2009.
(21) Ando, M.; Wada, T.; Sato, N. Facile one-pot synthesis of N-
difluoromethyl-2-pyridone derivatives. Org. Lett. 2006, 8, 3805–
3808.
(22) O’Shea, P. D.; Chen, C.-Y.; Chen, W.; Dagneau, P.; Frey, L. F.;
Grabowski, E. J. J.; Marcantonio, K. M.; Reamer, R. A.; Tan, L.;
Tillyer, R. D.; Roy, A.; Wang, X.; Zhao, D. Practical asymmetric
synthesis of a potent PDE4 inhibitor via stereoselective enolate
alkylation of a chiral aryl-heteroaryl secondary tosylate. J. Org.
Chem. 2005, 70, 3021–3030.
(23) Baker, W. R.; Shaopei, C.; Keeler, E. L. Nitroimidazole antibacter-
ial compounds and methods of use thereof. U.S. Patent 5,668,127,
1997.
(24) Imperiali, B.; Prins, T. J.; Fisher, S. L. Chemoenzymatic synthesis
of 2-amino-3-(2,20-bipyridinyl)propanoic acids. J. Org. Chem.
1993, 58, 1613–1616.
(25) Chuang, C.-L.; dos Santos, O.; Xu, X; Canary, J. W. Synthesis and
cyclic voltammetry studies of copper complexes of bromo- and
alkoxyphenyl-substituted derivatives of tris(2-pyridylmethyl)amine:
influence of cation-alkoxy interactions on copper redox potentials.
Inorg. Chem. 1997, 36, 1967–1972.
(26) van Hemel, J.; Esmans, E. L.; Alderweireldt, F. C.; Dommisse,
R. A.; de Groot, A. Synthesis and biological evaluation of some
acyclic pyridine C-nucleosides. Part one. Nucleosides Nucleotides
1994, 13, 2345–2366.
References
(1) Haydel, S. H. Extensively drug-resistant tuberculosis: a sign of the
times and an impetus for antimicrobial discovery. Pharmaceuticals
2010, 3, 2268–2290.
(2) World Health Organization. Global tuberculosis control: a short
update to the 2009 report. WHO Press: Geneva, Switzerland, 2009.
(3) Ma, Z.; Lienhardt, C.; McIlleron, H.; Nunn, A. J.; Wang, X.
Global tuberculosis drug development pipeline: the need and the
reality. Lancet 2010, 375, 2100–2109.
(4) Burman, W. J. Rip Van Winkle wakes up: development of tuber-
culosis treatment in the 21st century. Clin. Infect. Dis. 2010, 50,
S165–S172.
(5) Stover, C. K.; Warrener, P.; VanDevanter, D. R.; Sherman, D. R.;
Arain, T. M.; Langhorne, M. H.; Anderson, S. W.; Towell, J. A.;
Yuan, Y.; McMurray, D. N.; Kreiswirth, B. N.; Barry, C. E.;
Baker, W. R. A small-molecule nitroimidazopyran drug candidate
for the treatment of tuberculosis. Nature 2000, 405, 962–966.
(6) Matsumoto, M.; Hashizume, H.; Tomishige, T.; Kawasaki, M.;
Tsubouchi, H.; Sasaki, H.; Shimokawa, Y.; Komatsu, M. OPC-
67683, a nitro-dihydro-imidazooxazole derivative with promising
action against tuberculosis in vitro and in mice. PLoS Med. 2006, 3,
2131–2143.
(7) Anderson, R. F.; Shinde, S. S.; Maroz, A.; Boyd, M.; Palmer, B. D.;
Denny, W. A. Intermediates in the reduction of the antituberculosis
drug PA-824, (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-
6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine, in aqueous solution.
Org. Biomol. Chem. 2008, 6, 1973–1980.
(8) Singh, R.; Manjunatha, U.; Boshoff, H. I. M.; Ha, Y. H.; Niyom-
rattanakit, P.; Ledwidge, R.; Dowd, C. S.; Lee, I. Y.; Kim, P.;
Zhang, L.; Kang, S.; Keller, T. H.; Jiricek, J.; Barry, C. E. PA-824
kills nonreplicating Mycobacterium tuberculosis by intracellular
NO release. Science 2008, 322, 1392–1395.
(9) Diacon, A. H.; Pym, A.; Grobusch, M.; Patientia, R.; Rustomjee,
R.; Page-Shipp, L.; Pistorius, C.; Krause, R.; Bogoshi, M.; Church-
yard, G.; Venter, A.; Allen, J.; Palomino, J. C.; De Marez, T.; van
Heeswijk, R. P. G.; Lounis, N.; Meyvisch, P.; Verbeeck, J.; Parys,
W.; de Beule, K.; Andries, K.; McNeeley, D. F. The diarylquinoline
TMC207 for multidrug-resistant tuberculosis. N. Engl. J. Med.
2009, 360, 2397–2405.
(10) Palmer, B. D.; Thompson, A. M.; Sutherland, H. S.; Blaser, A.;
Kmentova, I.; Franzblau, S. G.; Wan, B.; Wang, Y.; Ma, Z.;
Denny, W. A. Synthesis and structure-activity studies of biphenyl
analogues of the tuberculosis drug (6S)-2-nitro-6-{[4-(trifluoro-
methoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine
(PA-824). J. Med. Chem. 2010, 53, 282–294.
(11) Barry, C. E.; Crick, D. C.; McNeil, M. R. Targeting the formation
of the cell wall core of M. tuberculosis. Infect. Disord.;Drug
Targets 2007, 7, 182–202.
(12) Sutherland, H. S.; Blaser, A.; Kmentova, I.; Franzblau, S. G.; Wan,
B.; Wang, Y.; Ma, Z.; Palmer, B. D.; Denny, W. A.; Thompson,
A. M. Synthesis and structure-activity relationships of antituber-
cular 2-nitroimidazooxazines bearing heterocyclic side chains.
J. Med. Chem. 2010, 53, 855–866.
(13) Rivers, E. C.; Mancera, R. L. New anti-tuberculosis drugs with
novel mechanisms of action. Curr. Med. Chem. 2008, 15, 1956–
1967.
(27) Jones, G.; Pitman, M. A.; Lunt, E.; Lythgoe, D. J.; Abarca, B.;
Ballesteros, R.; Elmasnaouy, M. Triazolopyridines. 18. Nucleo-
philic substitution reactions on triazolopyridines; a new route to
2,20-bipyridines. Tetrahedron 1997, 53, 8257–8268.
(28) Klunder, J. M.; Hoermann, M.; Cywin, C. L.;David, E.; Brickwood,
J. R.; Schwartz, R.; Barringer, K. J.; Pauletti, D.; Shih, C.-K.;
Erickson, D. A.; Sorge, C. L.; Joseph, D. P.; Hattox, S. E.; Adams,
J.; Grob, P. M. Novel nonnucleoside inhibitors of HIV-1 reverse
transcriptase. 7. 8-Arylethyldipyridodiazepinones as potent broad-
spectrum inhibitors of wild-type and mutant enzymes. J. Med.
Chem. 1998, 41, 2960–2971.
(29) van den Heuvel, M.; van den Berg, T. A.; Kellogg, R. M.; Choma,
C. T.; Feringa, B. L. Synthesis of a non-heme template for attach-
ing four peptides: an approach to artificial iron(II)-containing
peroxidases. J. Org. Chem. 2004, 69, 250–262.
(30) Sullivan, P. T.; Norton, S. J. R-Bromo- and R-chloropyridylala-
nines. J. Med. Chem. 1971, 14, 557–558.
(31) Jagusch, C.; Negri, M.; Hille, U. E.; Hu, Q.; Bartels, M.; Jahn-
Hoffmann, K.; Pinto-Bazurco Mendieta, M. A. E.; Rodenwaldt,
B.; Muller-Vieira, U.; Schmidt, D.; Lauterbach, T.; Recanatini,
M.; Cavalli, A.; Hartmann, R. W. Synthesis, biological evaluation
and molecular modelling studies of methyleneimidazole substi-
tuted biaryls as inhibitors of human 17R-hydroxylase-17,20-lyase
(CYP17). Part I: Heterocyclic modifications of the core structure.
Bioorg. Med. Chem. 2008, 16, 1992–2010.
(32) Schubert, U. S.; Eschbaumer, C.; Weidl, C. H. Synthesis of
5,500-bisfunctionalized 2,20:60,200-terpyridines using functionalized
pyridine building blocks. Synlett 1999, 342–344.
(33) Wilde, R. G.; Bakthavatchalam, R.; Beck, J. P.; Arvanitis, A.
Synthesis and use of imidazopyrimidines and imidazopyridines as
corticotropin releasing factor (CRF) antagonists. Patent WO
2001044248 A1, 2001.
(34) Apodaca, R.; Breitenbucher, J. G.; Chambers, A. L.; Deng, X.;
Hawryluk, N. A.; Keith, J. M.; Mani, N. S.; Merit, J. E.; Pierce,
J. M.; Seierstad, M.; Xiao, W. Preparation of aryl-hydroxyethyla-
mino-pyrimidines and triazines as modulators of fatty acid amide
hydrolase. Patent WO 2009105220 A1, 2009.
(35) Hegde, V. B.;Bis, S. J.;Yap, M. C. H.;Perreault, D. M.;Tisdell, F. G.;
Dintenfass, L. P.; Dripps, J. E.; Gifford, J. M.; Guenthenspberger,
K. A.; Karr, L. L.; Schoonover, J. R. Preparation of insecticidal
3-(2,6-disubstituted phenyl)-5-[4-(or 5-)arylthien-2-(or 3)yl]-1,2,
4-triazoles. Patent WO 2003024961 A1, 2003.
(36) Parmee, E. R.; Xiong, Y.; Guo, J.; Liang, R.; Brockunier, L.
Pyrazole derivatives as antidiabetic agents, their preparation,
pharmaceutical compositions and use in therapy. Patent US
2005272794 A1, 2005.
(14) Hu, Y.; Coates, A. R. M.; Mitchison, D. A. Comparison of the
sterilising activities of the nitroimidazopyran PA-824 and moxi-
floxacin against persisting Mycobacterium tuberculosis. Int. J.
Tuberc. Lung Dis. 2008, 12, 69–73.
(15) Mitchison, D. A.; Davies, G. R. Assessment of the efficacy of new
anti-tuberculosis drugs. Open Infect. Dis. J. 2008, 2, 59–76.
(16) Garcia-Contreras, L.; Sung, J. C.; Muttil, P.; Padilla, D.; Telko,
M.; VerBerkmoes, J. L.; Elbert, K. J.; Hickey, A. J.; Edwards, D. A.
Dry powder PA-824 aerosols for treatment of tuberculosis in
guinea pigs. Antimicrob. Agents Chemother. 2010, 54, 1436–1442.
(17) Kim, P.; Kang, S.; Boshoff, H. I.; Jiricek, J.; Collins, M.; Singh, R.;
Manjunatha, U. H.; Niyomrattanakit, P.; Zhang, L.; Goodwin,
M.; Dick, T.; Keller, T. H.; Dowd, C. S.; Barry, C. E. Structure-
activity relationships of antitubercular nitroimidazoles. 2. Deter-
minants of aerobic activity and quantitative structure-activity
relationships. J. Med. Chem. 2009, 52, 1329–1344.
(18) Noble, S. A.; Oshiro, G.; Malecha, J. W.; Zhao, C.; Robinson,
C. K. M.; Duron, S. G.; Sertic, M.; Lindstrom, A.; Shiau, A.;
Bayne, C.; Kahraman, M.; Lou, B.; Govek, S. Sulfonyl-substituted